Recent Press Releases

Perrigo Issues Shareholder Letter

DUBLIN, Nov. 9, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today issued the following shareholder letter: Perrigo Company November 9,...

Almirall's September YTD results 2015: operational business outperformance driven by Dermatology

Continued growth in Total Revenues +1.6% and Net Sales +0.5% (like-for-like). · Solid improvement of EBITDA (+13.0%). · Dermatology accounted for 42.5% of group...

U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 5, 2015-- Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved Genvoya® (elvitegravir 150...

Change in Board of Managing Directors to ensure continuity and focus on the future

Change in Board of Managing Directors to ensure continuity and focus on the future Prof Andreas Barner to move to Shareholders' Committee Hubertus von Baumbach to succeed as Chairman of the Board...

SANOFI ANNOUNCES NEW, GLOBAL BUSINESS UNIT STRUCTURE TO DRIVE FUTURE GROWTH

Deepens specialization and allows clear focus on growth drivers Three, new Global Business Units for General Medicines & Emerging Markets, Specialty Care, and Diabetes & Cardiovascular...

VIVUS Reports Third Quarter 2015 Financial Results

MOUNTAIN VIEW, CA -- (Marketwired) -- 11/04/15 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation...

Pfizer Expands its Patient Assistance Program, Doubling the Income Eligibility Limit to Benefit Even More Patients Taking Pfizer Medicines

Thursday, November 5, 2015 - 8:00am EST In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced today that it will...

Endo Reports Third Quarter 2015 Financial Results

DUBLIN, Nov. 5, 2015 /PRNewswire/ -- Third quarter revenues of $746 million, a 14 percent increase from third quarter of 2014 Third quarter reported $3.84 diluted (GAAP) loss per share from...

ASTRAZENECA ANNOUNCES YEAR-TO-DATE AND Q3 2015 RESULTS

Financial highlights1 Total Revenue stable in the YTD at $18,309m. Resilient top-line performance underpinned continued investment in R&D. Core R&D costs up by 18% in Q3, reflecting the...

Collins, McCaskill Open Senate Investigation into Rx Drug Pricing, Announce Intention to Hold Hearings

FOR IMMEDIATE RELEASE NOVEMBER 4, 2015 Contact: Drew Pusateri: 202-228-6263 Collins, McCaskill Open Senate Investigation into Rx Drug Pricing, Announce Intention to Hold Hearings Senators request...

Mylan Receives U.S. FTC Clearance for Proposed Acquisition of Perrigo and Confirms Governance Changes for the Combined Mylan-Perrigo Company

HERTFORDSHIRE, England and PITTSBURGH, Nov. 3, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Federal Trade Commission ("FTC") has cleared the company's proposed...

Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors

Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms. Elizabeth...

Zoetis to Acquire PHARMAQ, the Global Leader in Vaccines and Innovation for Health Products in Aquaculture

Purchase price of $765 million Strengthens core livestock business with industry-leading vaccines and pharmaceuticals for farmed fish, the fastest growing segment of animal health industry Gains...

Merck's Glucophage(R) Extended Release (XR) Can be Used for More Type 2 Diabetes Patients

 British regulatory authority approves Glucophage® Extended Release (XR) for type 2 diabetes patients with moderate renal impairment stage 3a or stable chronic heart failure  The approval is...

Shire to Acquire Dyax Corp, expanding and extending industry-leading Hereditary Angioedema (HAE) portfolio

Lead pipeline product, DX-2930, is a Phase 3-ready asset, offering potentially transformative prophylactic therapy for HAE DX-2930 has potential to expand HAE-treated patients and achieve annual...

Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee

10/30/2015 LAVAL, Quebec, Oct. 30, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that the ad hoc committee appointed by Valeant's board...

Valeant To Terminate Relationship With Philidor

10/30/2015 LAVAL, Quebec, Oct. 30, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it is severing all ties with Philidor Rx Services, LLC,...

Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization

Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization TARRYTOWN, N.Y., Oct. 30, 2015...

Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted EPS Increases 23% to $1.43

Mylan Expects to be at High End of Full Year 2015 Adjusted Diluted EPS Guidance Range of $4.15 to $4.35 Mylan Remains Steadfastly Committed To Our Value-Creating Offer for Perrigo HERTFORDSHIRE,...

ABBVIE REPORTS THIRD-QUARTER 2015 FINANCIAL RESULTS

- REPORTS THIRD-QUARTER ADJUSTED EPS OF $1.13, UP NEARLY 27 PERCENT AND EXCEEDING PREVIOUS GUIDANCE RANGE OF $1.04 TO $1.06; REPORTS GAAP EPS OF $0.74 - DELIVERS THIRD-QUARTER REVENUE OF $5.944...